Brinton Pharmaceuticals has got the approval of the Drugs Controller General of India (DCGI) for marketing favipiravir under the brand name Faviton for the management of mild to moderate COVID-19 patients.
In India, favipiravir was first approved by the regulatory authorities in June under emergency use authorization to treat coronavirus patients, the company said.
Faviton will be available in 200mg tablets and will also be exported globally, Brinton Pharmaceuticals said. The medicine will be available in strips of 10 tablets and boxes of 50 tablets, which is a rational pack for the treatment. It has a shelf life of 90 days.
“We always wanted to launch an evidence-based cure to combat covid-19. Our strategic intent will be to improve access through our strong distribution network. Which will help make Faviton available across all COVID treatment centres. The maximum retail price is ₹59 per tablet”. Said Rahulkumar Darda, chairman and managing director, Brinton Pharmaceuticals.
Furthermore, the number of patients getting cured and discharged has contributed to the increasing gap. Also between recoveries and total active cases, which was pegged at 436,015.
The Union government led by the All India Institute of Medical Sciences (AIIMS). Moreover, New Delhi with the aid of states and Union territories are co-coordinating their activities to control the novel Coronavirus.
Therefore, “The case fatality rate in India is 2.41% and is steadily declining. This has also helped in the reduction of the actual case load of COVID-19 cases”. Said the health ministry.
